Precision Medicine for Localized Prostate Cancer: Time to Move Beyond NCCN Risk Stratification?

Prostate cancer is the leading cause of cancer treatment–related years lived with disability for men worldwide.1 This has driven a disruptive change in management of favorable-risk prostate cancer such that nearly all National Comprehensive Cancer Network (NCCN) very low-risk patients are recommended conservative management rather than radical therapy.2 Simultaneously, at the other end of the risk spectrum, treatment intensification with more potent systemic therapies has been the subject of recent trials for men with higher-risk disease (eg, NCT02772588).

https://ift.tt/2RUaSiz